Evidence map›Paper›PMID 23090446›Full record

ReviewNature reviews. Nephrology2012

Assessing and improving the health-related quality of life of patients with ESRD.

Fredric O Finkelstein, Kelli L Arsenault, Ana Taveras, Kwabena Awuah, Susan H Finkelstein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Therapies for Chronic Allograft Rejection.Frontiers in pharmacology · 2021
    Review
  10. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2019
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Performance measures in dialysis facilities: what is the goal?Clinical journal of the American Society of Nephrology : CJASN · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fredric O FinkelsteinYale University School of Medicine, New Haven, CT 06510, USA. fof@comcast.net
Kelli L Arsenault
Ana Taveras
Kwabena Awuah
Susan H Finkelstein

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impairment of the health-related quality of life (HRQOL) of patients with end-stage renal disease (ESRD) is now well documented. These impairments involve a wide variety of domains and can be assessed using an array of well-validated instruments. Incorporation of at least some of these instruments into routine patient care is important in order to measure the physical and psychological impact of a disease and its treatment on the HRQOL of patients. How this implementation can be achieved in a practical way is, however, a challenge. As more research focuses on improving the HRQOL of patients with ESRD, the systematic evaluation of HRQOL and incorporation into patient care is becoming increasingly important. Whether strategies to improve the HRQOL of patients will translate into improved patient outcomes--as evidenced by reduced mortality and hospitalizations--and lower costs, remains to be determined.

Indexed as

Quality of LifeDepressionHumansKidney Failure, ChronicRenal Dialysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.